Results 81 to 90 of about 48,899 (192)

Integrative Omics Analysis Reveals a CD206+ Macrophage/Dendritic Cell–CD155–TIGIT+ Regulatory T Cell Axis as a Protective Immune Checkpoint Pathway in Atherosclerosis Progression

open access: yesBarrier Immunity, Volume 2, Issue 3, Page 131-146, September 2026.
ABSTRACT RNA sequencing (RNA‐seq) analysis revealed transcriptional features indicative of sustained immunosuppression within regulatory T cells (Tregs) isolated from atherosclerotic tissues, highlighting the critical contribution of immune checkpoint (ICP) receptor–ligand interactions to atherosclerosis progression. To comprehensively characterize the
Ying Shao   +16 more
wiley   +1 more source

Risk Factors for Cutaneous Immune‐Related Adverse Events in the Japanese Population: A Retrospective Single‐Center Cohort Study

open access: yesThe Journal of Dermatology, Volume 53, Issue 9, Page 1245-1260, September 2026.
ABSTRACT Immune checkpoint inhibitor (ICI)‐driven alterations in the immune system can induce immune‐related adverse events (irAEs). Cutaneous irAEs are notable for being the most common and for their early onset; however, the risk factors underlying their development and severity remain unclear. In this study, we retrospectively analyzed 1224 Japanese
Tomoya Watanabe   +4 more
wiley   +1 more source

Use of Emergency Department Extracorporeal Membrane Oxygenation for Treatment of Acute Necrotizing Myocarditis

open access: yesClinical Practice and Cases in Emergency Medicine, 2019
We report a case of acute necrotizing eosinophilic myocarditis (ANEM) secondary to drug rash with eosinophilia and systemic symptoms (DRESS) related to administration of minocycline.
Carly A. Loner, Peter W. Crane
doaj   +1 more source

Beyond Glucocorticoids: The Current Landscape and Prospects for Treating Immune Checkpoint Inhibitor‐Induced Autoimmunity

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
The rapid integration of immune checkpoint inhibitors (ICIs) into standard oncology protocols has birthed a new frontier in clinical rheumatology: immune‐related adverse events (irAEs). By disrupting the programmed cell death‐1 (PD‐1)/PD‐L1 and cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4) axes to restore antitumor T cell activity, these ...
Xizi Hu   +3 more
wiley   +1 more source

Eosinophillic Myocarditis Secondary to Metastatic Melanoma [PDF]

open access: yesRadiology: Cardiothoracic Imaging, 2019
Eosinophilic myocarditis is a rare form of myocarditis that may manifest from cancer-mediated inflammation. A case of eosinophilic myocarditis secondary to metastatic melanoma is described; metastatic melanoma can cause a T helper type 2 lymphocyte-mediated increase in circulating levels of interleukin-5, which is known to stimulate eosinophil ...
Robyn E. Bryde   +4 more
openaire   +3 more sources

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis With Polyangiitis: Findings From a Large European Cohort

open access: yesArthritis &Rheumatology, Volume 78, Issue 8, Page 1710-1717, August 2026.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis characterized by eosinophilia, asthma, and ear, nose, and throat (ENT) involvement. Although glucocorticoids (GCs) are effective in controlling symptoms, relapses and GC dependence are common. The aim of this study was to develop predictive models for vasculitis
Matthias Papo   +35 more
wiley   +1 more source

Fulminant Necrotizing Eosinophilic Myocarditis: A Case Report and Comprehensive Literature Review [PDF]

open access: yes, 2016
Acute eosinophilic myocarditis is a relatively rare disorder with serious morbidity and mortality. Due to its infrequency, standardized management guidelines are wanting.
Hager, Matthew   +4 more
core   +1 more source

Eosinophilic granulomatosis with polyangiitis-related myocarditis during mepolizumab therapy reveals a Th1/Th17-mediated vasculitic response

open access: yes, 2022
Eosinophilic granulomatosis with polyangiitis-related myocarditis during mepolizumab therapy reveals a Th1/Th17-mediated vasculitic ...
Annunziato, Francesco   +6 more
core   +1 more source

Closing the Translational Gap: Closed‐Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
Artificial intelligence accelerates cancer therapeutic development through an iterative, closed‐loop pipeline: from AI‐driven target and drug discovery, through automated synthesis and screening, to experimental validation in in vivo tumor models, culminating in clinical translation guided by patient data.
Tuğba Ören Varol, Mehmet Varol
wiley   +1 more source

Inflammatory cardiomyopathy - diagnosis and risk stratification in myocarditis [PDF]

open access: yes, 2020
Background: Acute myocarditis remains a challenging clinical diagnosis with limited epidemiological data and poorly defined markers of adverse risk. We sought to build a better understanding of myocarditis epidemiology and to integrate clinical, genetic
Lota, Amrit S.
core   +1 more source

Home - About - Disclaimer - Privacy